You are here

Phase III Trial Evaluates Novel Insulin Inhalation Powder for Type 2 Diabetes

Study results due this summer (June 17)

Follow-up visits have been completed for patients enrolled in a phase III trial of Afrezza (MannKind Corporation), an investigational inhalation powder consisting of human insulin for the treatment of type 2 diabetes. The ultra rapid-acting mealtime insulin therapy is administered via an inhaler. Findings from the study are expected to be released later this summer.

The trial assessed Afrezza in patients with type 2 diabetes whose disease was inadequately controlled with metformin, with or without a second or third oral medication. After a run-in period, during which the patients remained on their oral medication, 353 patients were randomly assigned to receive additional treatment with Afrezza or a placebo inhalation powder. The study also included a titration period, followed by a 12-week evaluation period, to assess hemoglobin A1c levels.

Administered at the start of a meal, Afrezza dissolves immediately upon inhalation and delivers insulin quickly to the bloodstream. Peak insulin levels are achieved within 12 to 14 minutes of administration, mimicking the release of meal-time insulin observed in healthy individuals. To date, the Afrezza clinical program has involved more than 5,600 adult patients.

Source: MannKind Corporation; June 17, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs
Acasti reports disappointing results for a second Omega-3-based drug